Skip to main content

Ionis Pharmaceuticals Inc

IONS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000874015

In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 4 sales; 515 institutions reported holding it in 13F filings for Q2 2026, worth $14.3B in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ionis Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $1.06M in total
Open-market sells
4 filings
4 insiders, $3.55M in total
Insiders trading
5
Net value
−$2.49M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ionis Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ionis Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Bennett C FrankEVP, Chief Scientific Officer60,128Sep 2, 20268
O'Neil Patrick R.EVP CLO & General Counsel59,205Sep 2, 202610
Monia Brett PChief Executive Officer242,760Sep 2, 202610
Birchler BrianEVP, Corp and Development Ops102,883Sep 2, 20268
Hayden Michael RDirector24,000IndirectJul 31, 20262
Reikes Peter NDirector14,222Jul 17, 20262
Hantson LudwigDirector–Jul 17, 20262
Herman Joan EDirector51,306Jul 17, 20263
Berthelsen Spencer RDirector161,233Jul 17, 20264
Diaz Allene M.Director3,811Jul 9, 20263
Kordasiewicz Holly B.EVP, Chief Development Officer22,096Jul 9, 20264
Yang Michael J.Director7,940Jul 6, 20262
Loscalzo JosephDirector36,330Jul 6, 20264
Klein Joseph IIIDirector11,014Jul 6, 20265
Baroldi JosephEVP, Chief Business Officer4,669IndirectJun 30, 20269
Schneider EugeneEVP, Chf Clinical Develop Ofcr77,114Jun 30, 20265
Swayze EricEVP Research21,759Jun 26, 20269
Parshall B LynneDirector51,344Apr 17, 20263
Jenne KyleEVP, Chf GL Pdt Str Ofcr23,713Apr 17, 20264
Devers Shannon L.EVP, Chief Human Resources Ofc16,348Apr 2, 20268
Hougen Elizabeth LEVP, Finance & CFO82,660Mar 18, 20265
Wender Joseph HDirector36,035IndirectDec 3, 20254
Geary Richard SEVP, Chief Development Officer59,657Nov 7, 20253
Cadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper Ofc35,788Sep 4, 20240
Muto Frederick TDirector59,597Jul 19, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 17, 2024 (view filing)Jan 125 daysSchneider EugeneEVP, Chf Clinical Develop OfcrSSale−8.00K$53.50−$428.0K−17.3%38.2K after10b5-1
Jan 18, 2024 (view filing)Jan 171 dayBaroldi JosephEVP, Chief Business OfficerSSale−1.46K$50.42−$73.6K−10.2%12.8K after
Jan 18, 2024 (view filing)Jan 171 dayBaroldi JosephEVP, Chief Business OfficerSSale−564$50.42−$28.4K−25.6%1.64K after
Jan 18, 2024 (view filing)Jan 171 dayBennett C FrankEVP, Chief Scientific OfficerSSale−6.75K$50.42−$340.1K−8.0%77.3K after
Jan 18, 2024 (view filing)Jan 171 dayGeary Richard SEVP, Chief Development OfficerSSale−7.34K$50.42−$370.0K−7.9%85.5K after
Jan 18, 2024 (view filing)Jan 171 dayHougen Elizabeth LEVP, Finance & CFOSSale−8.68K$50.42−$437.8K−8.7%90.9K after
Jan 18, 2024 (view filing)Jan 171 dayMonia Brett PChief Executive OfficerSSale−32.1K$50.42−$1.62M−17.2%154.1K after
Jan 18, 2024 (view filing)Jan 171 daySchneider EugeneEVP, Chf Clinical Develop OfcrSSale−5.48K$50.42−$276.4K−10.3%47.9K after
Jan 18, 2024 (view filing)Jan 171 daySwayze EricEVP ResearchSSale−6.30K$50.42−$317.4K−12.7%43.3K after
Jan 18, 2024 (view filing)Jan 171 daySwayze EricEVP ResearchSSale−9$50.42−$453.78−9.6%85 after
Jan 18, 2024 (view filing)Jan 171 dayBirchler BrianEVP, Corp and Development OpsSSale−4.50K$50.42−$226.7K−9.2%44.6K after
Jan 18, 2024 (view filing)Jan 171 dayO'Neil Patrick R.EVP CLO & General CounselSSale−7.74K$50.42−$390.5K−12.7%53.3K after
Jan 18, 2024 (view filing)Jan 171 dayCadoret-Manier OnaizaEVP, Chf GL Pdt Str & Oper OfcSSale−5.56K$50.42−$280.5K−14.1%33.8K after
Jan 29, 2024 (view filing)Jan 254 daysO'Neil Patrick R.EVP CLO & General CounselSSale−6.45K$51.75−$333.8K−12.1%46.8K after10b5-1
Jan 29, 2024 (view filing)Jan 254 daysMonia Brett PChief Executive OfficerSSale−2.29K$51.75−$118.2K−1.5%151.9K after10b5-1
Feb 2, 2024 (view filing)Jan 312 daysSwayze EricEVP ResearchSSale−10.8K$52.00−$560.2K−24.9%32.5K afterFrom original
Feb 16, 2024 (view filing)Feb 16Same dayMonia Brett PChief Executive OfficerSSale−387$44.49−$17.2K−0.2%173.8K after10b5-1
Apr 17, 2024 (view filing)Apr 161 dayBirchler BrianEVP, Corp and Development OpsSSale−905$41.66−$37.7K−1.9%46.2K after
Apr 17, 2024 (view filing)Apr 161 dayBaroldi JosephEVP, Chief Business OfficerSSale−4.01K$41.60−$166.6K−16.9%19.6K after
May 7, 2024 (view filing)May 34 daysKlein Joseph IIIDirectorSSale−6.00K$42.71−$256.3K−100.0%0 after6 lots10b5-1
Jun 20, 2024 (view filing)Jun 173 daysBerthelsen Spencer RDirectorSSale−16.0K$40.29−$644.6K−9.8%147.3K after10b5-1
Jul 17, 2024 (view filing)Jul 161 dayDiaz Allene M.DirectorSSale−1.64K$49.49−$81.0K−9.4%15.7K after2 lots10b5-1
Jul 17, 2024 (view filing)Jul 161 dayKlein Joseph IIIDirectorSSale−12.0K$50.00−$600.0K−100.0%0 after10b5-1
Aug 6, 2024 (view filing)Aug 51 dayGeary Richard SEVP, Chief Development OfficerSSale−2.43K$48.00−$116.6K−2.8%85.5K after10b5-1
Sep 3, 2024 (view filing)Aug 28-296 daysLateGeary Richard SEVP, Chief Development OfficerSSale−651$49.40−$32.2K−0.8%84.8K after2 lots10b5-1
Sep 4, 2024 (view filing)Feb 2215 daysBennett C FrankEVP, Chief Scientific OfficerSSale−1.89K$49.52−$93.3K−2.3%79.0K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysCadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper OfcSSale−2.16K$49.60−$107.2K−5.7%35.8K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysMonia Brett PChief Executive OfficerSSale−23.9K$49.37−$1.18M−12.1%173.7K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysSwayze EricEVP ResearchSSale−1.94K$49.56−$96.1K−5.4%34.3K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysSchneider EugeneEVP, Chf Clinical Develop OfcrSSale−2.11K$49.59−$104.4K−4.2%47.7K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysO'Neil Patrick R.EVP CLO & General CounselSSale−2.00K$49.67−$99.1K−3.9%48.6K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysHougen Elizabeth LEVP, Finance & CFOSSale−2.16K$49.54−$107.1K−2.3%92.9K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysGeary Richard SEVP, Chief Development OfficerSSale−2.00K$50.04−$99.8K−2.2%87.3K afterAmended
Oct 17, 2024 (view filing)Oct 161 daySwayze EricEVP ResearchSSale−53$38.31−$2.03K−25.2%157 after
Nov 14, 2024 (view filing)Nov 122 daysLoscalzo JosephDirectorSSale−13.5K$37.86−$511.4K−29.5%32.3K after10b5-1
Nov 14, 2024 (view filing)Nov 122 daysMonia Brett PChief Executive OfficerSSale−6.63K$38.05−$252.3K−3.8%167.4K after10b5-1
Nov 14, 2024 (view filing)Nov 122 daysSwayze EricEVP ResearchSSale−1.19K$37.92−$45.3K−3.4%33.7K after10b5-1
Dec 26, 2024 (view filing)Dec 233 daysHayden Michael RDirectorPPurchase+5.00K$36.22+$181.1K+16.5%35.2K after2 lots
Jan 17, 2025 (view filing)Jan 161 dayBaroldi JosephEVP, Chief Business OfficerSSale−3.40K$32.70−$111.2K−12.0%25.0K after
Jan 17, 2025 (view filing)Jan 161 dayBaroldi JosephEVP, Chief Business OfficerSSale−1.03K$32.70−$33.6K−25.1%3.07K after
Jan 17, 2025 (view filing)Jan 161 dayBennett C FrankEVP, Chief Scientific OfficerSSale−6.75K$32.90−$222.1K−6.9%90.9K after
Jan 17, 2025 (view filing)Jan 161 dayBirchler BrianEVP, Corp and Development OpsSSale−5.40K$32.70−$176.6K−8.9%55.1K after
Jan 17, 2025 (view filing)Jan 161 dayDevers Shannon L.EVP, Chief Human Resources OfcSSale−4.27K$32.78−$139.9K−21.1%15.9K after
Jan 17, 2025 (view filing)Jan 161 dayGeary Richard SEVP, Chief Development OfficerSSale−7.07K$32.86−$232.4K−6.8%96.7K after
Jan 17, 2025 (view filing)Jan 161 dayHougen Elizabeth LEVP, Finance & CFOSSale−8.87K$32.81−$291.0K−7.6%107.9K after
Jan 17, 2025 (view filing)Jan 161 dayMonia Brett PChief Executive OfficerSSale−33.4K$32.63−$1.09M−13.9%207.4K after
Jan 17, 2025 (view filing)Jan 161 dayO'Neil Patrick R.EVP CLO & General CounselSSale−7.36K$32.83−$241.6K−10.7%61.2K after
Jan 17, 2025 (view filing)Jan 161 daySchneider EugeneEVP, Chf Clinical Develop OfcrSSale−6.52K$32.79−$213.9K−10.0%58.5K after
Jan 17, 2025 (view filing)Jan 161 daySwayze EricEVP ResearchSSale−7.15K$32.84−$234.9K−13.5%45.7K after
Jan 17, 2025 (view filing)Jan 161 daySwayze EricEVP ResearchSSale−22$32.70−$719.4−10.7%184 after